Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Cash & Equivalents: 2012-2025

Historic Cash & Equivalents for Veracyte (VCYT) over the last 13 years, with Sep 2025 value amounting to $315.6 million.

  • Veracyte's Cash & Equivalents rose 15.14% to $315.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $315.6 million, marking a year-over-year increase of 15.14%. This contributed to the annual value of $239.1 million for FY2024, which is 10.46% up from last year.
  • According to the latest figures from Q3 2025, Veracyte's Cash & Equivalents is $315.6 million, which was up 43.77% from $219.5 million recorded in Q2 2025.
  • In the past 5 years, Veracyte's Cash & Equivalents registered a high of $327.5 million during Q2 2021, and its lowest value of $153.4 million during Q2 2022.
  • Its 3-year average for Cash & Equivalents is $224.3 million, with a median of $216.5 million in 2023.
  • As far as peak fluctuations go, Veracyte's Cash & Equivalents spiked by 122.14% in 2021, and later crashed by 53.15% in 2022.
  • Over the past 5 years, Veracyte's Cash & Equivalents (Quarterly) stood at $173.2 million in 2021, then declined by 10.94% to $154.2 million in 2022, then soared by 40.33% to $216.5 million in 2023, then increased by 10.46% to $239.1 million in 2024, then increased by 15.14% to $315.6 million in 2025.
  • Its Cash & Equivalents was $315.6 million in Q3 2025, compared to $219.5 million in Q2 2025 and $186.1 million in Q1 2025.